Krivokhizhin Igor Viktorovich (Postgraduate student, Department of Surgical Diseases, Medical Institute "Surgut State University", Oncologist, "Surgut District Clinical Hospital" Russia, Surgut)
Parsadanyan Ararat Mikichovich (MD, Professor, Department of Surgical Diseases, Medical Institute "Surgut State University", Chief oncologist, "Surgut District Clinical Hospital"
Russia, Surgut
)
| |
In today's modernizing world, breast cancer continues to occupy a leading position among all malignant neoplasms. At the same time, the presence of HER2+ status in breast cancer patients indicates an unfavorable course of the disease and a worse prognosis. With the advent of targeted drugs in the medical community, primarily trastuzumab, the relationship of the disease with the presence of HER2+ status has completely changed. But at the same time, resistance to anti-HER2 drugs is regularly found in the routine work of an oncologist, in particular, in the long-term treatment of metastatic breast cancer. In this regard, many resistance mechanisms have been identified in order to create new anti-HER2 agents and introduce them into clinical practice. This article presents the central mechanisms of resistance to anti-HER2 agents, ways to resolve them, and in addition presents a clinical case of a patient who has developed resistance to treatment.
Keywords:breast cancer, resistance, anti-HER2 agents, dimerization, tyrosine kinase pathway, lapatinib, trastuzumab
|
|
| |
|
Read the full article …
|
Citation link:
Krivokhizhin I. V., Parsadanyan A. M. ACQUIRED RESISTANCE TO ANTI-HER2 AGENTS: CAUSES AND SOLUTIONS // Современная наука: актуальные проблемы теории и практики. Серия: Естественные и Технические Науки. -2024. -№11/2. -С. 186-190 DOI 10.37882/2223-2966.2024.11-2.19 |
|
|
LEGAL
INFORMATION:
